| Trial ID: | L1687 |
| Source ID: | NCT01327924
|
| Associated Drug: |
Norditropin Nordiflex®
|
| Title: |
Usability and Tolerability of the Norditropin NordiFlex® Injection Device in Children Never Previously Treated With Growth Hormone
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Growth Hormone Disorder|Growth Hormone Deficiency in Children|Genetic Disorder|Turner Syndrome|Foetal Growth Problem|Small for Gestational Age|Chronic Kidney Disease|Chronic Renal Insufficiency|Delivery Systems
|
| Interventions: |
DRUG: Norditropin NordiFlex®
|
| Outcome Measures: |
Primary: Usability of growth hormone injection device assessed by a quantitative scale, after 3 months of growth hormone treatment | Secondary: Number of adverse events, from 0 - 3 months of growth hormone treatment|Number of technical complaints, from 0 to 3 months of growth hormone treatment
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
CHILD
|
| Phases: |
|
| Enrollment: |
77
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2011-04
|
| Completion Date: |
2012-06
|
| Results First Posted: |
|
| Last Update Posted: |
2014-06-24
|
| Locations: |
Paris La défense cedex, 92932, France
|
| URL: |
https://clinicaltrials.gov/show/NCT01327924
|
